Please login to the form below

Not currently logged in
Email:
Password:

MHRA chair Breckenridge to advise UK on healthcare ethics

Sir Alasdair Breckenridge appointed first chair of the Emerging Science and Bioethics Advisory Committee

Professor Sir Alasdair Breckenridge - MHRA chairChair of the UK's Medicines and Healthcare products Regulatory Agency (MHRA), Sir Alasdair Breckenridge, has been appointed the first chair of the Emerging Science and Bioethics Advisory Committee at the country's Department of Health (DH).

The new committee has been formed to advise UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications.

"I am delighted that Sir Alasdair has agreed to chair this important new committee,” said the DH's chief medical officer, Dame Sally Davies.

“He brings with him a level of experience that is difficult to match, plus a reputation for delivering high calibre debate and advice on serious scientific issues.”

In addition to his MHRA experience, Sir Alasdair's previous roles include serving as a member of the Adverse Reactions Group, and the Subcommittee on Adverse Reactions to Vaccines and Immunisation of the MHRA precursor, the Committee on Safety of Medicines (CSM).

Between 1992 and 1996 he was a member of the Medical Research Council, and he has worked closely on several programmes of the European Union, the World Health Organization and the International Union of Pharmacology.

Sir Alasdair takes up the position immediately, and will remain in the role for two years while also serving for the MHRA.

23rd May 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...

Infographics